Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Leading a new pattern in China's inhalation preparation market: The launch conference for HealthGen's new product "Shutanlin" was grandly held!
Published Time：
2020-02-19
Multinational pharmaceutical giants have long held over 90% of the Chinese market for inhalation preparations related to respiratory diseases. This market has been called the "highest-end and most difficult segment in the generic drug field." This year, Joincare Pharmaceutical Group Industry Co., Ltd.'s "Shutanlin" (compound ipratropium bromide solution for inhalation) was approved for listing. The listing of "Shutanlin" has milestone significance for the R&D of domestic inhalation preparations, and its appearance will lead a new pattern in the domestic inhalation preparation market.
On September 6, Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Healthy Yuan Group") held a grand new product launch satellite meeting themed "Healthy Breathing, Yuan Qi You Wo" at the Wuhan International Conference Center. Professor Huang Mao, Director of the Respiratory Department and Respiratory Disease Research Institute of Jiangsu Provincial People's Hospital; Professor Song Yuanlin, Director of the Respiratory and Critical Care Medicine Department of Huashan Hospital Affiliated to Fudan University, and doctoral supervisor; and Professor Cui Yongyao, from the Department of Pharmacology, Shanghai Jiao Tong University School of Medicine, attended the meeting and gave wonderful speeches.
As Healthy Yuan Group's first approved inhalation preparation, the appearance of "Shutanlin" (compound ipratropium bromide solution for inhalation) at this meeting allowed nearly 10,000 respiratory-related clinicians from across the country to learn about this drug, the first to pass the consistency evaluation and the first new Class 4 registered and approved nebulized inhalation solution among all domestic respiratory inhalation preparations, for the first time through the introduction of authoritative experts.
It is reported that the listing of "Shutanlin" has milestone significance for the R&D of domestic inhalation generic drugs: Currently, chronic respiratory diseases have become the third leading cause of chronic disease death in China. However, due to the high barriers to R&D, approval, and production of inhalation preparations, this market has been dominated by foreign companies for a long time. In order to seize the development opportunities in the respiratory drug market, Healthy Yuan Group conducted in-depth research in this field, establishing Shanghai Fangyu Healthy Pharmaceutical Technology Co., Ltd., led by Professor Jin Fang, a member of the Chinese Pharmacopoeia Commission and former director of the Shanghai Respiratory System Drug Engineering and Technology Research Center of the Shanghai Pharmaceutical Industry Research Institute, and jointly established Guangzhou Healthy Yuan Respiratory Drug Engineering and Technology Co., Ltd. with the Guangzhou Institute of Respiratory Diseases, presided over by Academician Zhong Nanshan of the Chinese Academy of Engineering, an expert in respiratory diseases and a medical authority, investing heavily in the R&D of respiratory drugs and accumulating rich experience in inhalation preparation technology.
On April 9 this year, Healthy Yuan Group announced that it had received the "Drug Registration Approval Document" issued by the National Medical Products Administration, and "Shutanlin" (compound ipratropium bromide solution for inhalation) was approved for listing as a new Class 4 registration application. Previously, only Boehringer Ingelheim's original "Tiotropium" was on sale domestically, and Healthy Yuan Group is the first generic manufacturer. It can be said that the listing of "Shutanlin" meets the needs of many domestic patients to use high-quality domestic drugs.
It is worth mentioning that at the meeting, Professor Cui Yongyao from the Department of Pharmacology, Shanghai Jiao Tong University School of Medicine, also introduced another inhalation preparation about to be approved by Healthy Yuan Group—"Lishutong" (salbutamol hydrochloride nebulized inhalation solution). It is the first domestically produced new Class 3 registered and approved nebulized inhalation solution, which means that "Lishutong" will also be the first salbutamol to be listed in China. Compared with the imported or domestic salbutamol already on the market in China, "Lishutong" has the characteristics of small dosage, high efficacy, and high safety. This another "first" for Healthy Yuan Group means that it will continue to provide Chinese doctors with more and better choices, benefiting more asthma and chronic obstructive pulmonary disease patients, and also demonstrating Healthy Yuan Group's confidence and strength in the field of inhalation preparations.
Currently, Healthy Yuan Group is on the eve of an outbreak in the respiratory inhalation preparation market, and its subsidiary Lizhu Group's biopharmaceutical business is also in a stage of explosive growth. It is believed that after "Shutanlin" and "Lishutong," Healthy Yuan Group will become increasingly stable in the innovation and R&D of inhalation preparations. The series of upcoming inhalation preparation products are even more anticipated!
Source: Sohu.com
Previous Page
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.